Rafik El Beblawy: Evolving Role of Perioperative Immunotherapy in Resectable NSCLC
Rafik El Beblawy/X

Rafik El Beblawy: Evolving Role of Perioperative Immunotherapy in Resectable NSCLC

Rafik El Beblawy, internal medicine physician and hospitalist, shared a post on X:

“Excited to share our editorial commentary in Journal of Thoracic Disease on the AEGEAN trial and the evolving role of perioperative immunotherapy in resectable NSCLC.”

Title: Efficacy without compromising resection: surgical outcomes from AEGEAN

Authors: Rafik ElBeblawy, Chinmay T. Jani, Sanad Alhushki, Aakash Desai

Read the Full Article.

Rafik El Beblawy: Evolving Role of Perioperative Immunotherapy in Resectable NSCLC